Drug, enzyme and peptide delivery using erythrocytes as carriers

Millán, Carmen Gutiérrez; Marinero, Marı́a Luisa Sayalero; Castañeda, Aránzazu Zarzuelo; Lanao, José M.

doi:10.1016/j.jconrel.2003.11.018

Cited by 170 publications

(108 citation statements)

References 118 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Owing to their biocompatibility, EGs have been studied for use as vehicles for delivering various biologically active substances, including chemical drugs, enzymes and peptides [10][11][12]. Our previous study showed that EGs can be used as an in vivo delivery system for plasmid DNA [5], and others have used EGs to encapsulate peptide nucleic acid (PNA) for delivery into macrophages in vitro [13].…”

Section: Discussionmentioning

confidence: 99%

Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides

Kim

Hou

et al. 2009

Biomaterials

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides

Kim

Hou

et al. 2009

Biomaterials

View full text Add to dashboard Cite

“…Compared to plasma, erythrocytes are unique in blood. Erythrocytes are potential biocompatible vectors for different bioactive substances, including oligonucleotides [21,22]. Red blood cells have been successfully used to deliver modified oligonucleotides [23].…”

Section: Discussionmentioning

confidence: 99%

In vivo and in vitro differences between leukocytic uptake of oligodeoxynucleotides

Zhang

Schluesener

2008

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Development and application of therapeutic oligonucleotides rely on proper analysis of binding and uptake. We have used several model oligodeoxynucleotides (ODNs) to analyze binding/uptake by rat and human leukocytes. Here we describe: (1) differences between in vivo and in vitro uptake of ODNs to rat leukocytes, (2) differences after injection of lipopolysaccharide (LPS), (3) large in vitro differences between primary mononuclear cells in PBS, plasma and blood, and (4) differences of ODN uptake between rat and human leukocytes. Our data show that ODN uptake by primary blood cells was different in PBS, plasma and blood. In addition, LPS treatment increased ODN uptake by leukocytes in blood, indicating that pathological conditions may influence ODN uptake. Furthermore, ODN uptake in rat and human blood is also different, suggesting that preclinical ODN uptake data from rat blood cannot easily be extrapolated to the human condition.

show abstract

“…The system can regulate the biocompatibility of the erythrocytes and molecules on or in the erythrocytes, and thus prolong the bioavailability of the molecules in blood. Erythrocytes can also be used as a reservoir to allow slow release of drug or protein at a sustained therapeutic level [2,17,32]. Murciano et al [33] explored an innovative method in which tPA was coupled to the surface of erythrocytes and targeted the tPA-erythrocyte conjugate to blood clots.…”

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo degradation of Aβ peptide by peptidases coupled to erythrocytes

et al. 2007

View full text Add to dashboard Cite

It is generally believed that amyloid β peptides (Aβ) are the key mediators of Alzheimer's disease. Therapeutic interventions have been directed toward impairing the synthesis or accelerating the clearance of Aβ. An equilibrium between blood and brain Aβ exists mediated by carriers that transport Aβ across the blood brain barrier. Passive immunotherapy has been shown to be effective in mouse models of AD, where the plasma borne antibody binds plasma Aβ causing an efflux of Aβ from the brain. As an alternative to passive immunotherapy we have considered the use of Aβ-degrading peptidases to lower plasma Aβ levels. Here we compare the ability of three Aβ-degrading peptidases Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access

show abstract

Drug, enzyme and peptide delivery using erythrocytes as carriers

Cited by 170 publications

References 118 publications

Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides

Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides

In vivo and in vitro differences between leukocytic uptake of oligodeoxynucleotides

In vitro and in vivo degradation of Aβ peptide by peptidases coupled to erythrocytes

Contact Info

Product

Resources

About